OT: Rare, any thoughts on medicure and cabg? Maybe they'll have better luck than alxn....market cap is just $140M where as alxn lost $300M in market cap when primo cabg bit the dust....
Press Release Source: Medicure Inc.
Medicure Inc.: MC-1 Phase II MEND-CABG Data to be Presented at 2006 Scientific Sessions of the American Heart Association
Monday October 30, 7:30 am ET
WINNIPEG, MANITOBA--(MARKET WIRE)--Oct 30, 2006 -- Medicure Inc. (TSX:MPH.TO - News)(AMEX:MCU - News), a cardiovascular focused biopharmaceutical company, today announced that an abstract describing the results from the Phase II MEND-CABG study will be presented at the 2006 Scientific Sessions of the American Heart Association (AHA), which is being held November 12-15, 2006 in Chicago, Illinois. The 901 patients MEND-CABG study was completed in 2006 with the results demonstrating the clinical benefits of MC-1 in reducing cardiovascular events in patients undergoing coronary artery bypass graft (CABG) surgery.
The abstract titled, "Protective Effect of Pyridoxal-5-phosphate on Perioperative Myocardial Infarction is not Dependent of Aortic Cross Clamp Time: Results from the MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Trial" will be presented by Dr. Michel Carrier, Director of Cardiovascular Surgery Program, Montreal Heart Institute (MHI) between 3:00 PM and 4:30 PM Central Time, Sunday November 12th in a poster session in Hall A2 of the McCormick Place Convention Center.
"I am pleased to participate in the AHA Scientific Sessions, one of the premier cardiology conferences in the world, and look forward to discussing the use of MC-1 to prevent cardiovascular events in CABG patients," commented Dr. Carrier. "As the principal investigator for the upcoming Phase III study with MC-1 in CABG patients, I look forward to evaluating this therapy in a larger patient population. The cardiovascular community will be intently watching the outcome of this Phase III study, as its result could have a significant benefit and lasting impact on how CABG patients are treated."
About Medicure Inc.
Medicure is a biopharmaceutical company focused on the research, development and commercialization of novel compounds to treat cardiovascular disorders. The Company's solid position in this field is highlighted by the following:
- Two drugs, MC-1 & MC-4232, in late stage clinical development
- Four positive Phase II trials completed with MC-1
- FDA Fast Track designation for MC-1
- U.S. rights to AGGRASTAT® Injection (tirofiban hydrochloride)
- Dual action antithrombotic, MC-45308, with positive preclinical results
Medicure also has a medicinal chemistry based Drug Discovery program focused on discovery and advancement of novel small molecule anti-ischemics and antithrombotics towards human clinical studies. |
